Shares of Core Laboratories NV (NYSE:CLB) dropped 3.2% during trading on Thursday . The company traded as low as $119.92 and last traded at $119.92, with a volume of 389,252 shares trading hands. The stock had previously closed at $123.87.

CLB has been the subject of a number of recent analyst reports. Morgan Stanley upped their price objective on shares of Core Laboratories NV from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Tuesday, April 19th. JPMorgan Chase & Co. restated a “buy” rating on shares of Core Laboratories NV in a research report on Thursday, June 30th. Zacks Investment Research upgraded shares of Core Laboratories NV from a “hold” rating to a “buy” rating and set a $138.00 price objective for the company in a research report on Wednesday. Citigroup Inc. upped their price objective on shares of Core Laboratories NV from $115.00 to $123.00 and gave the company a “neutral” rating in a research report on Monday, May 16th. Finally, Stephens upped their price objective on shares of Core Laboratories NV from $89.00 to $98.00 and gave the company an “equal weight” rating in a research report on Friday, April 22nd. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $121.00.

The company has a market cap of $5.01 billion and a PE ratio of 51.19. The firm’s 50-day moving average is $123.33 and its 200-day moving average is $113.45.

Core Laboratories NV (NYSE:CLB) last posted its quarterly earnings results on Wednesday, July 20th. The company reported $0.35 earnings per share for the quarter, meeting the consensus estimate of $0.35. During the same period last year, the firm posted $0.81 earnings per share. The company earned $148.10 million during the quarter, compared to the consensus estimate of $146.37 million. The company’s revenue for the quarter was down 27.4% on a year-over-year basis. Equities analysts anticipate that Core Laboratories NV will post $1.62 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Shareholders of record on Monday, July 18th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 1.86%. The ex-dividend date is Thursday, July 14th.

A number of large investors recently bought and sold shares of CLB. WCM Investment Management CA increased its stake in Core Laboratories NV by 44.5% in the fourth quarter. WCM Investment Management CA now owns 3,188,453 shares of the company’s stock valued at $346,713,000 after buying an additional 981,243 shares during the period. Howland Capital Management LLC increased its stake in Core Laboratories NV by 4.7% in the fourth quarter. Howland Capital Management LLC now owns 102,070 shares of the company’s stock valued at $11,099,000 after buying an additional 4,562 shares during the period. Swiss National Bank increased its stake in Core Laboratories NV by 1.2% in the fourth quarter. Swiss National Bank now owns 77,200 shares of the company’s stock valued at $8,395,000 after buying an additional 900 shares during the period. Aberdeen Asset Management PLC UK bought a new stake in Core Laboratories NV during the fourth quarter valued at $5,554,000. Finally, Teacher Retirement System of Texas increased its stake in Core Laboratories NV by 1,393.1% in the fourth quarter. Teacher Retirement System of Texas now owns 44,404 shares of the company’s stock valued at $4,828,000 after buying an additional 41,430 shares during the period.

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.